^
    Back
    Association details:
    Biomarker:KIT exon 9 mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    To compare the efficacy of sunitinib and imatinib following cytoreductive resection in GIST patients with progression on imatinib: A multi-center controlled study.

    Published date:
    05/16/2018
    Excerpt:
    Patients carrying a primary KIT exon 11 mutation had a PFS of 31 months in sunitinib compared with 11 months in imatinib (p = 0.036), respectively. The PFS of sunitinib group was longer than that of imatinib group (30.0 months vs 12.0 months, p = 0.009).
    DOI:
    10.1200/JCO.2018.36.15_suppl.11530
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Gastrointest Oncol
    Title:

    Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review

    Excerpt:
    ...the clinical benefit of second line sunitinib can be quite impressive in the treatment of metastatic GIST with an exon 9 mutation.
    DOI:
    10.21037/jgo.2016.09.15